Novo Holdings participates in portfolio company Amolyt Pharma’s $138 million financing
- Amolyt is developing therapeutic peptides for rare endocrine and related diseases, including AZP-3601 (eneboparatide) for hypoparathyroidism
- Proceeds will fund the Phase 3 programme for hypoparathyroidism, as well as its growing endocrine pipeline
Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, has announced it has invested in a €130 million (approx. $138 million) Series C Financing by its portfolio company, Amolyt Pharma SAS.